Today men with prostate cancer have larger prostates

被引:33
作者
Feneley, MR
Landis, P
Simon, I
Metter, EJ
Morrell, CH
Carter, HB
Walsh, PC
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[2] NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA
[3] Loyola Coll, Dept Math Sci, Baltimore, MD 21210 USA
关键词
D O I
10.1016/S0090-4295(00)00738-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To examine the relationship between prostate size and the method of cancer detection in men with organ-confined prostate cancer, and compare prostate size in men with and without cancer. Methods. Prostate volume was evaluated in 720 men who had undergone radical prostatectomy for Stage Tie or Stage T2 cancer. Men with Stage T2 cancer were divided into those treated before 1989 (when widespread prostate-specific antigen [PSA] testing began), or not. Gland volume was also examined in 265 men participating in the Baltimore Longitudinal Study of Aging who had no clinical evidence of cancer. Volumes were compared using linear regression to allow for age. Results. Prostate volume in men with Stage Tie cancer was statistically significantly larger than in men with Stage T2 cancer diagnosed in the pre-PSA era after adjusting for age (P = 0.0001), and statistically significantly larger than in men without cancer above age 47 years based on 95% confidence intervals. Prostate volumes in men with Stage T2 cancer diagnosed in the pre-PSA era and in men without cancer were not statistically significantly different. Conclusions. Prostate volume in men with PSA-detected, organ-confined cancer is larger than in men with palpable organ-confined cancer diagnosed in either the pre-PSA era or PSA era. These discrepancies may reflect a diagnostic bias due to the effect of benign prostatic hyperplasia on serum PSA that results in the selection of men with larger prostates for biopsy. UROLOGY 56: 839-842, 2000. (C) 2000, Elsevier Science Inc.
引用
收藏
页码:839 / 842
页数:4
相关论文
共 7 条
[1]   A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Tomaszewski, JE ;
Wein, A .
UROLOGY, 1998, 52 (04) :631-636
[2]   New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia [J].
De Marzo, AM ;
Coffey, DS ;
Nelson, WG .
UROLOGY, 1999, 53 (03) :29-40
[3]  
MCNAUGHTON CM, 1997, JAMA-J AM MED ASSOC, V278, P1516
[4]   THE EFFECT OF NAFARELIN ACETATE, A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST, ON BENIGN PROSTATIC HYPERPLASIA [J].
PETERS, CA ;
WALSH, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (10) :599-604
[5]   ACCURACY OF INVIVO ASSESSMENT OF PROSTATIC VOLUME BY MRI AND TRANSRECTAL ULTRASONOGRAPHY [J].
RAHMOUNI, A ;
YANG, A ;
TEMPANY, CMC ;
FRENKEL, T ;
EPSTEIN, J ;
WALSH, P ;
LEICHNER, PK ;
RICCI, C ;
ZERHOUNI, E .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1992, 16 (06) :935-940
[6]   Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia [J].
Roehrborn, CG ;
Boyle, P ;
Gould, AL ;
Waldstreicher, J .
UROLOGY, 1999, 53 (03) :581-589
[7]  
Shock NW., 1984, NORMAL HUMAN AGING B